Page last updated: 2024-12-05
methyl ricinoleate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
methyl ricinoleate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5354133 |
| CHEMBL ID | 3183150 |
| CHEBI ID | 156194 |
| SCHEMBL ID | 290360 |
| MeSH ID | M0046637 |
Synonyms (58)
| Synonym |
|---|
| nsc-1254 |
| ricinoleic acid methyl ester |
| methyl ricinolate |
| flexricin p-1 |
| nsc1254 |
| ricinoleic acid, methyl ester |
| methyl ricinoleate |
| 141-24-2 |
| methyl ricinoleate, >=99% (gc) |
| methyl (9z,12r)-12-hydroxyoctadec-9-enoate |
| 9-octadecenoic acid, 12-hydroxy-, methyl ester, (9z,12r)- |
| methyl (z,12r)-12-hydroxyoctadec-9-enoate |
| CHEBI:156194 |
| R0029 |
| ricinolic acid methyl ester |
| NCGC00248854-01 |
| 9-octadecenoic acid, 12-hydroxy-, methyl ester, [r-(z)]- |
| tox21_200861 |
| dtxcid509169 |
| dtxsid2029169 , |
| NCGC00258415-01 |
| cas-141-24-2 |
| 9-octadecenoic acid, 12-hydroxy-, methyl ester, (r-(z))- |
| einecs 205-472-3 |
| hsdb 5636 |
| 9-octadecenoic acid, 12-hydroxy-, methyl ester, (theta-(z))- |
| 9-octadecenoic acid, 12-hydroxy-, methyl ester |
| nsc 1254 |
| unii-90fdr3o96y |
| 90fdr3o96y , |
| 12-hydroxy-9-octadecenoic acid, methyl ester |
| ai3-10523 |
| methyl 12-d-hydroxy-9-cis-octadecenoate |
| cis-ricinoleic acid methyl ester |
| methyl ricinoleate [inci] |
| ricinic acid methyl ester |
| dub rm |
| ricinoleic acid, methyl ester [hsdb] |
| methyl ricinoleate [usp-rs] |
| SCHEMBL290360 |
| methyl (9z)-12-hydroxy-9-octadecenoate # |
| CHEMBL3183150 |
| mfcd00046712 |
| methyl 12-hydroxyoleate |
| 9-octadecenoic acid,12-hydroxy-, methyl ester, (9z,12r)- |
| methyl ricinoleate, analytical standard |
| AKOS027320383 |
| AS-70362 |
| methyl ricinoleate, european pharmacopoeia (ep) reference standard |
| ricinoleic acid-methyl ester |
| 41989-07-5 |
| methyl ricinoleate, united states pharmacopeia (usp) reference standard |
| (r,z)-methyl 12-hydroxyoctadec-9-enoate |
| 12r-hydroxy-9-cis-octadecenoic acid methyl ester |
| methyl 12-hydroxy-9(z)-octadecenoate |
| Q27271321 |
| CS-0139029 |
| HY-N8045 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| aliphatic alcohol | An alcohol derived from an aliphatic compound. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (6)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.0122 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 30.7625 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 68.8687 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 55.2100 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 61.9466 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 15.5603 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (4.55%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (95.45%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||